Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified)

DM1-Y73

Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified)

Mertansine (DM-1) is a tubulin inhibitor that binds to the ends of microtubules and inhibits microtubule dynamics. DM-1(Mertansine) has antitumor activity and functions as a regulator of tubulin. It is an alpha-amino acid ester, a carbamate, an epoxide, an organic heterocyclic tetracyclic compound, an organochlorine compound, a mercaptan, and a maydenin alkaloid. DM-1, derived from Mydenin, is a cytotoxic component of antibody-drug conjugations that produce antibody-drug conjugations via a sulfhydryl group splice with SPP (n-succinimide 4- (2-pyridyl dithio)) or SMCC (4- (3-mercapto-2, 5-dioxy-1 pyrrolidyl) -cyclohexanic acid) splice.

658.8 €

DM1-BLY73

Biotinylated Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified)

Mertansine (DM-1) is a tubulin inhibitor that binds to the ends of microtubules and inhibits microtubule dynamics. DM-1(Mertansine) has antitumor activity and functions as a regulator of tubulin. It is an alpha-amino acid ester, a carbamate, an epoxide, an organic heterocyclic tetracyclic compound, an organochlorine compound, a mercaptan, and a maydenin alkaloid. DM-1, derived from Mydenin, is a cytotoxic component of antibody-drug conjugations that produce antibody-drug conjugations via a sulfhydryl group splice with SPP (n-succinimide 4- (2-pyridyl dithio)) or SMCC (4- (3-mercapto-2, 5-dioxy-1 pyrrolidyl) -cyclohexanic acid) splice.

658.8 €

SN8-M685

Monoclonal Anti-SN38 Antibody, Mouse IgG1 (MALS verified)

SN-38 is an antineoplastic drug. It is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor) but has 1000 times more activity than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1. The variant of UGT1A1 in ~10% of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form. SN-38 and its glucuronide are lost into the bile and intestines. It can cause the symptoms of diarrhoea and myelosuppression experienced by ~25% of the patients administered irinotecan.

5459.16 €

MBS190264-5x02mg

Human Transcription Factor IIB MonoclonalAntibody

2881.62 €

MBS190112-01mg

Corticotropin-Releasing Factor MonoclonalAntibody

892.62 €

MBS190112-5x01mg

Corticotropin-Releasing Factor MonoclonalAntibody

3372.5 €